Search results for Mosunetuzumab

Mosunetuzumab Biosimilar – Anti-CD3E, MS4A1, CD20 mAb – Research Grade, ProteoGenix, PX-TA1482

Description of Mosunetuzumab Biosimilar - Anti-CD3E, MS4A1, CD20 mAb - Research Grade The Structure of Mosunetuzumab Biosimilar Mosunetuzumab Biosimilar is a monoclonal antibody (mAb) that specifically targets three proteins – CD3E, MS4A1, and CD20. It is a biosimilar version of the original Mosunetuzumab, which was developed by Genentech and is currently in clinical trials for the treatment of non-Hodgkin’s lymphoma. The biosimilar version is being developed by a different pharmaceutical company and is intended for research purposes only. The structure of Mosunetuzumab Biosimilar is similar to that of the original Mosunetuzumab, with a few minor differences. It is a humanized IgG1 antibody, meaning that it is derived from human antibodies and has been modified to reduce immunogenicity. It consists of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to the target proteins, while the constant region is responsible for effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The Activity of Mosunetuzumab Biosimilar Mosunetuzumab Biosimilar is a bispecific antibody, meaning that it can bind to two different proteins at the same time. It binds to CD3E on T cells and MS4A1 on B cells, bringing these two cell types into close proximity. This leads to the activation of T cells, which then release cytokines and other molecules that help to kill the targeted B cells. In addition, Mosunetuzumab Biosimilar also binds to CD20 on B cells, triggering their death through ADCC and CDC. The ability of Mosunetuzumab Biosimilar to target multiple proteins and activate different immune mechanisms makes it a promising therapeutic option for the treatment of various B cell malignancies. It has shown particularly promising results in the treatment of non-Hodgkin’s lymphoma, where it has demonstrated high response rates in clinical trials. The Application of Mosunetuzumab Biosimilar Mosunetuzumab Biosimilar is currently being developed for research purposes only and is not yet approved for clinical use. However, it has the potential to be used as a therapeutic agent for the treatment of various B cell malignancies, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and multiple myeloma. In addition to its potential as a monotherapy, Mosunetuzumab Biosimilar also has the potential to be used in combination with other therapies, such as chemotherapy or other targeted therapies. Its bispecific nature and ability to activate different immune mechanisms make it a promising candidate for combination therapy, as it can potentially enhance the efficacy of other treatments. Overall, Mosunetuzumab Biosimilar has shown great promise as a potential therapeutic option for the treatment of B cell malignancies. Its unique structure, targeting multiple proteins, and ability to activate different immune mechanisms make it a versatile and potentially effective treatment option. Further research and clinical trials will be needed to fully understand its potential and determine its safety and efficacy in treating these diseases.

Mosunetuzumab, Abbexa, abx831441

Mosunetuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD3E/MS4A1/CD20, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells. Mosunetuzumab simultaneously binds to CD3 epsilon (CD3ε), a component of the T-cell receptor (TCR) complex, and to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies. This results in crosslinking of the TCR, inducing downstream signaling events that lead to B-cell killing.

Mosunetuzumab ELISA Kit, ProteoGenix, KPTX178

Description of Mosunetuzumab ELISA Kit Introduction The Mosunetuzumab ELISA Kit is a highly sensitive and specific tool used for the detection and quantification of Mosunetuzumab, a novel bispecific antibody targeting CD3 and CD20. This kit is an essential component in the development and evaluation of Mosunetuzumab, a promising therapeutic agent for the treatment of B-cell malignancies. Structure of Mosunetuzumab Mosunetuzumab is a bispecific antibody that simultaneously binds to both CD3 and CD20 on the surface of B-cells. It is composed of two single-chain variable fragments (scFv) targeting CD3 and CD20, connected by a flexible linker. This unique structure allows for the simultaneous activation of T-cells through CD3 and the depletion of B-cells through CD20, resulting in a potent anti-tumor effect. Activity of Mosunetuzumab Mosunetuzumab has shown promising activity in preclinical studies, with potent anti-tumor effects in various B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. It has also demonstrated superior activity compared to other CD3-CD20 bispecific antibodies, due to its unique structure and binding affinity. The mechanism of action of Mosunetuzumab involves the activation of T-cells and the subsequent killing of B-cells through the formation of immunological synapses. This results in the release of cytotoxic granules and the induction of apoptosis in the targeted B-cells. In addition, Mosunetuzumab has been shown to have a longer half-life and increased stability compared to other bispecific antibodies, making it a more effective therapeutic agent. Application of Mosunetuzumab ELISA Kit The Mosunetuzumab ELISA Kit is a crucial tool for the development and evaluation of Mosunetuzumab as a therapeutic agent. It allows for the quantification of Mosunetuzumab levels in various biological samples, such as serum, plasma, and cell culture supernatants. This kit is also used in pharmacokinetic studies to determine the absorption, distribution, metabolism, and excretion of Mosunetuzumab in vivo. It provides accurate and reliable data on the pharmacokinetic profile of Mosunetuzumab, which is essential for the optimization of dosage and treatment regimens. In addition, the Mosunetuzumab ELISA Kit is a valuable tool for monitoring the efficacy of Mosunetuzumab in clinical trials. It allows for the quantification of Mosunetuzumab levels in patient samples, which can be correlated with clinical outcomes. This enables researchers to assess the relationship between drug exposure and response, and to identify potential biomarkers for patient selection and treatment response. Conclusion The Mosunetuzumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Mosunetuzumab, a novel bispecific antibody targeting CD3 and CD20. Its unique structure and potent activity make it a promising therapeutic agent for the treatment of B-cell malignancies. The application of this kit in the development and evaluation of Mosunetuzumab is crucial for its successful translation into clinical practice.

Mosunetuzumab ELISA Kit, Abbexa, abx395067

This product is currently in development. The lead time for this product may be several months. Please contact us at [email protected] for an updated lead time before purchasing this product. Mosunetuzumab ELISA Kit is a quantitative ELISA kit for detection of Mosunetuzumab.Polatuzumab vedotin is an active ingredient of Polivy, a drug product for the treatment of previously treated adult patients with diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab. Polatuzumab vedotin is an antibody-drug conjugate composed of a humanized monoclonal antibody (mAb) targeting B-cell antigen receptor complex-associated protein beta chain (CD79b) and a microtubule-disrupting toxin, monomethyl auristatin E (MMAE). This drug was developed by Genentech/Roche using a proprietary technology developed by Seattle Genetics. In 2018, orphan designation was granted for polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma by the European Commission to Roche Registration Limited. Based on the effective therapeutic effect of polatuzumab vedotin on DLBCL, the U.S. Food and Drug Administration (FDA) granted accelerated approval to polatuzumab vedotin, in combination with bendamustine plus rituximab on 10 June 2019. Subsequently, the European Medicines Health and Therapeutic Goods Administration of Australian Drug Regulatory Administration also approved Polivy's sales authorization from Genentech. Besides DLBCL, polatuzumab vedotin also has been investigated in the treatment of non-hodgkins lymphoma, chronic lymphocytic leukemia, follicular lymphoma. Some of the trials were complicated, and there are six clinical trials still undergoing now. For example, there is a phase Ib/II study investigating the safety, tolerability, pharmacokinetics, and efficacy of mosunetuzumab (BTCT4465A) in combination with chop or chp-polatuzumab vedotin in participants with b-cell non-hodgkin lymphoma. Furthermore, a study to evaluate the safety and efficacy of polatuzumab vedotin in combination with rituximab, gemcitabine and oxaliplatin compared to rituximab, gemcitabine and oxaliplatin alone in participants with relapsed or refractory diffuse large B-cell lymphoma is recruiting. The recent events of polatuzumab vedotin is that Chugai Pharmaceutical, another developer, adverse events data from a phase ii (jo40762/p-drive) trial diffuse large B-cell lymphoma and announces intention to submit NDA to Ministry of Health, Labour and Welfare for diffuse large B-cell lymphoma in Japan on February 2020. At the same period, a phase-II clinical trials in diffuse large B cell lymphoma is undergoing in United Kingdom (IV).

Mosunetuzumab Biosimilar - Research Grade, ichor.bio, ICH5026

Detects human CD3/CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Mosunetuzumab.

Research Grade Mosunetuzumab (HY257166), abinScience, HY257166